Zhang et al. (Science China Life Sciences, 2016) reported that intraventricular transplantation of neural stem cells derived from syngeneic mouse induced pluripotent stem cells (iPSC-NSCs) into mice with experimental autoimmune encephalomyelitis (EAE) both remyelinated damaged spinal cord and unexpectedly reduced CNS T-cell infiltration. Their paper leaves three issues unresolved on the road toward clinical translation: the mechanism of the anti-inflammatory effect — the authors state that the mechanisms underlying the reduction of CNS inflammation are unclear and offer only the hypothesis that repaired tissue loses the ability to recruit new lymphocytes —; the long-term tumorigenicity risk from residual undifferentiated cells; and whether human or non-human primate iPSC-NSCs would replicate the efficacy and limited immunogenicity seen in syngeneic mice, the experiments the authors explicitly call for to speed up clinical development. A decade of follow-up literature has partially illuminated but not resolved these questions: adjacent studies established LIF-mediated and regulatory-T-cell-mediated mechanisms for related grafts; human iPSC-NSCs were shown to engraft long-term without tumor formation in mice; and two completed phase-1 trials transplanted non-iPSC-derived human neural stem cells into progressive MS patients safely. However, no iPSC-NSC study in human or non-human primate form has entered MS trials, and 2026 reviews still list mechanism, long-term survival, and immunological responses as open.

Background

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) in which focal infiltration of T lymphocytes and other immune cells damages myelin sheaths and axons. Existing drugs suppress inflammation but do not repair accumulated tissue damage, which is the dominant problem in the progressive phase of the disease. Experimental autoimmune encephalomyelitis (EAE) — induced in mice by immunization with myelin antigens such as the MOG35-55 peptide (a fragment of myelin oligodendrocyte glycoprotein, MOG) — is the standard animal model of MS. Neural stem/progenitor cells (NSCs, also called NPCs) are self-renewing CNS cells that can differentiate into neurons, astrocytes, and oligodendrocytes (the myelin-producing cells), making them candidate agents for replacing lost cells and remyelinating denuded axons. Two bottlenecks restricted this strategy: a limited supply of clinical-grade human NSCs, and immune rejection of grafted cells. Induced pluripotent stem cells (iPSCs) — adult cells reprogrammed to an embryonic-stem-cell-like pluripotent state — promise an unlimited, potentially patient-matched source of NSCs (in genetically identical, 'syngeneic' recipients), but raise concerns of their own: residual undifferentiated pluripotent cells in the differentiated product can form tumors (teratomas) after transplantation, and some iPSC-derived cell types have proved unexpectedly immunogenic even in autologous recipients, while others induce tolerance. Work before 2016 had established that transplanted NSCs/NPCs benefit EAE animals largely through 'bystander' effects — secreted trophic and immunomodulatory factors — rather than direct cell replacement: transplanted mouse iPSC-derived neural precursors were shown to protect CNS tissue in EAE via secretion of leukemia inhibitory factor (LIF), which preserves oligodendrocytes and limits blood-brain-barrier damage, thereby reducing infiltration of blood-borne leukocytes (Laterza et al., 2013); and human fetal-derived NSCs ameliorated EAE in non-human primates (Pluchino et al., 2009). In this landscape, Zhang et al. (2016) generated NSCs from C57BL/6 mouse iPSCs and transplanted them into the lateral ventricles of syngeneic mice with MOG35-55-induced chronic EAE. Compared with vehicle and with allogeneic (genetically mismatched) NSCs that were rejected and ineffective, the iPSC-NSC grafts differentiated into neurons, integrated into damaged tissue, promoted remyelination, dramatically reduced infiltration of CD3+/CD4+/CD8+ T cells (total, helper, and cytotoxic T lymphocytes distinguished by their CD surface-marker proteins) in the spinal cord, and improved clinical scores and motor function; in vitro, the syngeneic iPSC-NSCs did not activate recipient T-cell proliferation. The authors state that the mechanisms underlying this reduction of CNS inflammation are unclear — offering the hypothesis that repaired tissue loses the ability to recruit new lymphocytes — note that tumor formation from residual undifferentiated cells is an unresolved safety issue (their monitoring lasted about three months), and explicitly call for experiments using human or non-human primate iPSC-derived NSCs to evaluate therapeutic efficacy as the outstanding task for clinical development.

Problem Statement

Zhang et al. (2016) showed that intraventricular transplantation of syngeneic mouse iPSC-derived neural stem cells into mice with chronic MOG35-55 EAE both repairs tissue (neuronal integration, remyelination) and unexpectedly reduces CNS T-cell infiltration, and left three linked open questions bearing on clinical translation. (1) Mechanism: the mechanisms underlying the reduction of CNS inflammation and T-cell infiltration are unclear. The authors propose one hypothesis — that tissue repaired by the graft loses the ability to recruit new lymphocytes — leaving open whether reduced lymphocyte recruitment is secondary to structural repair, is actively produced by the graft (for example through secreted immunomodulatory mediators, induction of local tolerance, or recruitment of regulatory T cells), or is a combination of these. Which mechanism(s) operate for iPSC-NSC grafts in autoimmune demyelination, and in what relative contribution? (2) Long-term safety and tumorigenicity: residual undifferentiated cells within iPSC-derived neural preparations have been reported to cause tumor formation in other lineages, and the source study monitored animals for only about three months. Do iPSC-NSC grafts — in particular human iPSC-NSC preparations intended for clinical use — remain free of tumor formation and other adverse outcomes over extended post-transplantation periods, including in an immune-mediated demyelinating CNS environment? (3) Cross-species efficacy and immunogenicity: efficacy and negligible immunogenicity were demonstrated only in syngeneic mouse recipients. Do neural stem cells derived from human or non-human primate iPSCs replicate the therapeutic efficacy and limited immunogenicity seen in the mouse EAE model — the experiments the authors explicitly identify as the outstanding task for clinical development? The three components of the question are mechanism for the source's iPSC-NSC grafts in autoimmune demyelination, long-term safety for human iPSC-NSC preparations in an immune-mediated demyelinating CNS environment, and cross-species efficacy and immunogenicity for human or non-human primate iPSC-NSCs. The first concerns the mechanism(s) of the reduced CNS inflammation and T-cell infiltration and their relative contribution, discriminating repair-secondary from graft-active immunomodulation; the second concerns absence of tumor formation and other adverse outcomes from iPSC-NSC grafts over post-transplantation periods well beyond the source study's roughly three-month monitoring; and the third concerns therapeutic efficacy with limited immunogenicity of human or non-human primate iPSC-derived NSCs.

References

  1. Zhang C, Cao J, Li X, Xu H, Wang W, Wang L, Zhao X, Li W, Jiao J, Hu B, Zhou Q, Zhao T (2016). Treatment of multiple sclerosis by transplantation of neural stem cells derived from induced pluripotent stem cells. Science China Life Sciences 59(9):950-957. DOI: 10.1007/s11427-016-0114-9. https://doi.org/10.1007/s11427-016-0114-9
  2. Laterza C, Merlini A, De Feo D, Ruffini F, Menon R, Onorati M, Fredrickx E, Muzio L, Lombardo A, Comi G, Quattrini A, Taveggia C, Farina C, Cattaneo E, Martino G (2013). iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF. Nature Communications 4:2597. DOI: 10.1038/ncomms3597. https://doi.org/10.1038/ncomms3597
  3. Pluchino S, Gritti A, Blezer E, Amadio S, Brambilla E, Borsellino G, Cossetti C, Del Carro U, Comi G, 't Hart B, Vescovi A, Martino G (2009). Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Annals of Neurology 66(3):343-354. DOI: 10.1002/ana.21745. https://doi.org/10.1002/ana.21745
  4. Drago D, Basso V, Gaude E, Volpe G, Peruzzotti-Jametti L, Bachi A, Musco G, Andolfo A, Frezza C, Mondino A, Pluchino S (2016). Metabolic determinants of the immune modulatory function of neural stem cells. Journal of Neuroinflammation 13(1):232. DOI: 10.1186/s12974-016-0667-7. https://doi.org/10.1186/s12974-016-0667-7
  5. McIntyre LL, Greilach SA, Othy S, Sears-Kraxberger I, Wi B, Ayala-Angulo J, Vu E, Pham Q, Silva J, Dang K, Rezk F, Steward O, Cahalan MD, Lane TE, Walsh CM (2020). Regulatory T cells promote remyelination in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis following human neural stem cell transplant. Neurobiology of Disease 140:104868. DOI: 10.1016/j.nbd.2020.104868. https://doi.org/10.1016/j.nbd.2020.104868
  6. Willis CM, Nicaise AM, Hamel R, Pappa V, Peruzzotti-Jametti L, Pluchino S (2020). Harnessing the neural stem cell secretome for regenerative neuroimmunology. Frontiers in Cellular Neuroscience 14:590960. DOI: 10.3389/fncel.2020.590960. https://doi.org/10.3389/fncel.2020.590960
  7. Luciani M, Garsia C, Beretta S, Cifola I, Peano C, Merelli I, Petiti L, Miccio A, Meneghini V, Gritti A (2024). Human iPSC-derived neural stem cells displaying radial glia signature exhibit long-term safety in mice. Nature Communications 15:9433. DOI: 10.1038/s41467-024-53613-7. https://doi.org/10.1038/s41467-024-53613-7
  8. Doi D, Magotani H, Kikuchi T, Ikeda M, Hiramatsu S, Yoshida K, Amano N, Nomura M, Umekage M, Morizane A, Takahashi J (2020). Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease. Nature Communications 11:3369. DOI: 10.1038/s41467-020-17165-w. https://doi.org/10.1038/s41467-020-17165-w
  9. Genchi A, Brambilla E, Sangalli F, Radaelli M, Bacigaluppi M, Furlan R, Andolfo A, Drago D, Magagnotti C, Scotti GM, Greco R, Vezzulli P, Ottoboni L, Bonopane M, Capilupo D, Ruffini F, Belotti D, Cabiati B, Cesana S, Matera G, Leocani L, Martinelli V, Moiola L, Vago L, Panina-Bordignon P, Falini A, Ciceri F, Uglietti A, Sormani MP, Comi G, Battaglia MA, Rocca MA, Storelli L, Pagani E, Gaipa G, Martino G (2023). Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study. Nature Medicine 29(1):75-85. DOI: 10.1038/s41591-022-02097-3. https://doi.org/10.1038/s41591-022-02097-3
  10. Schoonheim MM, Strijbis EMM (2023). Repair what is lost: neuroprotection through neural stem cells in progressive MS. Cell Reports Medicine 4(3):100985. DOI: 10.1016/j.xcrm.2023.100985. https://doi.org/10.1016/j.xcrm.2023.100985
  11. Leone MA, Gelati M, Profico DC, Gobbi C, Pravatà E, Copetti M, Conti C, Abate L, Amoruso L, Apollo F, Balzano RF, Bicchi I, Carella M, Ciampini A, Colosimo C, Crociani P, D'Aloisio G, Di Viesti P, Ferrari D, Fogli D, Fontana A, Frondizi D, Grespi V, Kuhle J, Laborante A, Lombardi I, Muzi G, Paci F, Placentino G, Popolizio T, Ricciolini C, Sabatini S, Silveri G, Spera C, Stephenson D, Stipa G, Tinella E, Zarrelli M, Zecca C, Ventura Y, D'Alessandro A, Peruzzotti-Jametti L, Pluchino S, Vescovi AL (2023). Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive multiple sclerosis. Cell Stem Cell 30(12):1597-1609. DOI: 10.1016/j.stem.2023.11.001. https://doi.org/10.1016/j.stem.2023.11.001
  12. Harris VK, Stark J, Williams A, Roche M, Malin M, Kumar A, Carlson AL, Kizilbash C, Wollowitz J, Andy C, Gerber LM, Sadiq SA (2024). Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial. Stem Cell Research & Therapy 15(1):151. DOI: 10.1186/s13287-024-03765-6. https://doi.org/10.1186/s13287-024-03765-6
  13. Mozafari S, Deboux C, Laterza C, Ehrlich M, Kuhlmann T, Martino G, Baron-Van Evercooren A (2021). Beneficial contribution of induced pluripotent stem cell-progeny to Connexin 47 dynamics during demyelination-remyelination. Glia 69(5):1094-1109. DOI: 10.1002/glia.23950. https://doi.org/10.1002/glia.23950
  14. Malladi AR, Abbasi Kasbi N, Cohen JA, Stuve O (2026). Induced pluripotent stem cell treatment for microglia replacement in progressive MS. Multiple Sclerosis Journal, published online July 21, 2026. DOI: 10.1177/13524585261459847. https://doi.org/10.1177/13524585261459847
  15. Razzaghi E, Azari A, Golchin A, Mihanfar A (2026). Neural stem cells in multiple sclerosis: a comprehensive review of preclinical and clinical evidence for CNS repair and translational hurdles. Applied Biochemistry and Biotechnology, published online August 4, 2026. DOI: 10.1007/s12010-026-05865-w. https://doi.org/10.1007/s12010-026-05865-w